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BACKGROUND
Rituximab added to chemotherapy prolongs survival among adults with B-cell can-
cer. Data on its efficacy and safety in children with high-grade, mature B-cell 
non-Hodgkin’s lymphoma are limited.
METHODS
We conducted an open-label, international, randomized, phase 3 trial involving 
patients younger than 18 years of age with high-risk, mature B-cell non-Hodgkin’s 
lymphoma (stage III with an elevated lactate dehydrogenase level or stage IV) or 
acute leukemia to compare the addition of six doses of rituximab to standard 
lymphomes malins B (LMB) chemotherapy with standard LMB chemotherapy 
alone. The primary end point was event-free survival. Overall survival and toxic 
effects were also assessed.
RESULTS
Analyses were based on 328 patients who underwent randomization (164 patients 
per group); 85.7% of the patients had Burkitt’s lymphoma. The median follow-up 
was 39.9 months. Events were observed in 10 patients in the rituximab–chemo-
therapy group and in 28 in the chemotherapy group. Event-free survival at 3 years 
was 93.9% (95% confidence interval [CI], 89.1 to 96.7) in the rituximab–chemo-
therapy group and 82.3% (95% CI, 75.7 to 87.5) in the chemotherapy group (hazard 
ratio for primary refractory disease or first occurrence of progression, relapse after 
response, death from any cause, or second cancer, 0.32; 95% CI, 0.15 to 0.66; one-
sided P = 0.00096, which reached the significance level required for this analysis). 
Eight patients in the rituximab–chemotherapy group died (4 deaths were disease-
related, 3 were treatment-related, and 1 was from a second cancer), as did 20 in 
the chemotherapy group (17 deaths were disease-related, and 3 were treatment-
related) (hazard ratio, 0.36; 95% CI, 0.16 to 0.82). The incidence of acute adverse 
events of grade 4 or higher after prephase treatment was 33.3% in the rituximab–
chemotherapy group and 24.2% in the chemotherapy group (P = 0.07); events were 
related mainly to febrile neutropenia and infection. Approximately twice as many 
patients in the rituximab–chemotherapy group as in the chemotherapy group had 
a low IgG level 1 year after trial inclusion.
CONCLUSIONS
Rituximab added to standard LMB chemotherapy markedly prolonged event-free 
survival and overall survival among children and adolescents with high-grade, 
high-risk, mature B-cell non-Hodgkin’s lymphoma and was associated with a 
higher incidence of hypogammaglobulinemia and, potentially, more episodes of 
infection. (Funded by the Clinical Research Hospital Program of the French Min-
istry of Health and others; ClinicalTrials.gov number, NCT01516580.)
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Cure rates among children and ad-olescents with high-grade, mature B-cell non-Hodgkin’s lymphoma (mainly Burkitt’s 
lymphoma but also diffuse large B-cell lympho-
ma) have dramatically improved over the past 30 
years, with trials showing survival of approxi-
mately 90%.1-4 However, well-known prognostic 
factors such as higher stage, elevated lactate 
dehydrogenase (LDH) level, leukemic bone mar-
row, and central nervous system (CNS) involve-
ment and treatment-related factors such as lack 
of early or complete response can identify pa-
tients at high risk for treatment failure.
Rituximab has shown efficacy in adults with 
B-cell cancers, including diffuse large B-cell 
lymphoma and Burkitt’s lymphoma, and is con-
sidered to be the standard of care in addition to 
chemotherapy in most patients with high-grade 
B-cell non-Hodgkin’s lymphoma. The outcome 
in children and adolescents with B-cell non-
Hodgkin’s lymphoma receiving chemotherapy 
alone is superior to that in adults; therefore, the 
potential benefits of rituximab must be balanced 
against potential unexpected and severe toxic 
effects. Furthermore, subtypes of mature B-cell 
non-Hodgkin’s lymphoma differ between adults 
and children in terms of molecular anomalies 
that may confer different prognoses and sensi-
tivities to treatments.5,6
A phase 2 trial involving children showed that 
rituximab was active as a single-agent therapy 
for high-grade, high-risk, mature B-cell non-
Hodgkin’s lymphoma and could be safely added 
to the lymphomes malins B (LMB) chemotherapy 
regimen.7 Therefore, we conducted an interna-
tional, randomized, phase 3 trial (Inter-B-NHL 
ritux 2010) to establish whether the addition of 
rituximab to LMB chemotherapy could improve 
event-free survival among children and adoles-
cents with high-grade, high-risk, mature B-cell 
non-Hodgkin’s lymphoma or leukemia.
Me thods
Trial Oversight and Design
In this trial, we investigated the efficacy and 
safety of adding rituximab to a modified LMB 
chemotherapy regimen. This academic trial in-
volved two international cooperative groups — 
the European Intergroup for Childhood Non-
Hodgkin Lymphoma (EICNHL) and the Children’s 
Oncology Group (COG) — spanning 12 coun-
tries (see the Supplementary Appendix, available 
with the full text of this article at NEJM.org). 
The trial sponsors were Gustave Roussy (for 
countries in the EICNHL) and COG (for Austra-
lia, Canada, and the United States) and included a 
partnership with F. Hoffmann–La Roche–Genen-
tech, which provided partial funding and pro-
vided rituximab at no cost but had no role in the 
design or conduct of the trial nor in the prepara-
tion of the manuscript. The manuscript was 
written by the authors, who vouch for the accu-
racy and completeness of the data and for the 
fidelity of the trial to the protocol, available at 
NEJM.org.
Parents and patients (if age appropriate) signed 
informed consent and assent forms before enroll-
ment. The research protocol was approved in 
each country by the necessary ethics and regula-
tory committees. An international, independent 
data and safety monitoring committee, which 
included two pediatric oncologists, one adult on-
cologist, and one statistician, monitored progress 
and interim analysis reports.
Randomization was performed separately for 
patients at the EICNHL and COG sites. For pa-
tients at the EICHNL sites, randomization was 
performed centrally at Gustave Roussy with the 
use of a minimization algorithm that accounted 
for histologic features (large-cell or non–large-
cell), therapeutic group (B, C1, C3; defined in 
the next subsection), and the national group. To 
avoid predictability, a probability of 0.80 to as-
sign the treatment that minimized imbalance 
was used. For patients at the COG sites, random-
ization was performed centrally at the COG data 
center, with the use of block randomization 
stratified according to histologic features and 
therapeutic group. Physicians and patients were 
aware of the treatment-group assignments.
Patients
Eligible patients were 6 months to 18 years of 
age and had newly diagnosed high-grade, mature 
B-cell neoplasms (Burkitt’s lymphoma; diffuse 
large B-cell lymphoma; or high-grade, mature 
B-cell non-Hodgkin’s lymphoma not otherwise 
specified) and advanced St. Jude stage disease 
(stage III with an LDH level that was more than 
twice the institutional upper limit of the normal 
range or any stage IV or leukemia presentation). 
Patients with primary mediastinal (thymic) large 
B-cell lymphoma were not eligible. Pathological 
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slides were centrally reviewed at the national 
level, but centralized review was not mandatory 
before enrollment. Detailed inclusion and exclu-
sion criteria and initial workup data are provided 
in the Supplementary Appendix.
Therapeutic groups were defined as in the 
French–American–British (FAB)/LMB96 interna-
tional study for all patients except those with 
blasts in cerebrospinal f luid (CSF), who were 
treated with high-dose methotrexate that was 
administered as a 24-hour infusion (group C3).3,4 
The rationale for this modification was a retro-
spective review of previous LMB studies that 
showed poorer survival among these patients 
than among other patients in group C.8 In the 
FAB/LMB96 study, outcomes in patients in group 
B who had stage I, II, or III disease with an LDH 
level that was equal to or less than twice the up-
per limit of the normal range were excellent 
(event-free survival, 95%). Therefore, with regard 
to group B, only patients who had stage III dis-
ease and an LDH level that was more than twice 
the upper limit of the normal range or non-CNS 
stage IV disease with bone marrow involvement 
of less than 25% were eligible for this trial. 
Patients in group C1 had CSF-negative stage IV 
disease with bone marrow involvement of at 
least 25% (leukemia presentation), CNS-positive 
disease, or both. Group C3 included patients 
with CSF-positive stage IV disease.
Treatment
Chemotherapy was administered according to the 
FAB/LMB96-based protocol, with some minor 
modifications (Fig. S1 in the Supplementary Ap-
pendix).3,4 All the patients received prephase treat-
ment with low-dose cyclophosphamide, vincris-
tine, and prednisone (COP regimen). Patients in 
group B received four cycles of chemotherapy, 
which was similar to the therapy used in group 
B4 in the FAB/LMB96 study. For all the patients 
in group C, the maintenance chemotherapy was 
reduced to two courses, in contrast to the four 
maintenance cycles that were used in the FAB/
LMB96 study. Information about monitoring the 
risk of jeopardizing efficacy with this reduction 
in therapy is presented in the Supplementary Ap-
pendix. Patients in group C1 received high-dose 
methotrexate (at a dose of 8 g per square meter 
of body-surface area) over a period of 4 hours, 
as in the FAB/LMB96 study, whereas patients in 
group C3 (whose disease was CSF-positive) re-
ceived high-dose methotrexate (at a dose of 8 g 
per square meter) over a period of 24 hours. 
Consecutive courses were administered as soon 
as blood counts recovered and the patient’s con-
dition allowed, except for the maintenance cours-
es, which were administered at 28-day intervals.
Rituximab was administered as an intravenous 
infusion (at a dose of 375 mg per square meter) 
on day 2 before (i.e., day −2) and day 1 of each 
of the two induction chemotherapy courses and 
on day 1 of each of the two consolidation courses, 
for a total of six doses.7 When a course had to 
be postponed, rituximab was administered at the 
planned time in order to ensure the intensity of 
the therapy.
An initial response evaluation was performed 
on day 7 after the receipt of the COP regimen. 
Patients in groups B and C1 who had a reduction 
in the tumor size of less than 20% were switched 
to a more intensive therapeutic group (i.e., from 
group B to C1 or from group C1 to C3). Remis-
sion assessment was performed after receipt of 
the first consolidation course in group B and 
after receipt of the second consolidation course 
in group C. In patients with a residual mass as 
assessed by radiographic evaluation, an excision 
or biopsy for pathological review was recom-
mended. If a biopsy was not performed, the pa-
tients were to continue receiving the assigned 
treatment. For patients in group B, if viable tu-
mor cells were identified, the therapy was 
switched to the more intensive regimen that was 
given to patients in group C1. Patients in group 
C1 or C3 with biopsy-proven viable tumor cells 
after the second consolidation course (continu-
ous infusion and high-dose cytarabine and eto-
poside, with or without rituximab [depending on 
the randomly assigned treatment group]) were 
considered to have primary refractory disease 
and were considered to have had an event; such 
patients discontinued the protocol therapy. No 
treatment decisions were to be based on the re-
sults of 18F-fluorodeoxyglucose positron-emission 
tomography–computed tomography.
End Points
The primary end point was event-free survival, 
which was defined as the minimum time be-
tween randomization and the detection of residu-
al viable tumor cells after receipt of the second 
consolidation course of therapy (i.e., primary re-
fractory disease), relapse, progressive disease, 
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second cancer, or death from any cause, or the 
date of the last follow-up for patients who did 
not have any event. All events were validated by 
the steering committee. Details of the secondary 
end points (overall survival, complete remission 
at assessment time, toxic effects, and immune 
reconstitution as assessed by IgG levels) are pre-
sented in the Supplementary Appendix.
Statistical Analysis
We expected the 3-year event-free survival to be 
84% on the basis of data from the FAB/LMB96 
study.3,4 Because this trial was designed to deter-
mine the efficacy of adding rituximab to stan-
dard treatment, a one-sided test was used. At a 
one-sided 5% level of statistical significance and 
assuming randomization in a 1:1 ratio, we cal-
culated that 72 events would need to be observed 
in order for the trial to have 90% power to detect 
a hazard ratio of 0.50 (on the basis of an ex-
pected 3-year event-free survival of 84% in the 
chemotherapy group and 92% in the rituximab–
chemotherapy group). It was estimated that 600 
patients would need to undergo randomization 
in order for 72 events to be observed.
Interim analyses for efficacy with the use of 
the Lan–DeMets alpha-spending function ap-
proach applied to an O’Brien–Fleming boundary, 
truncated at 3 SD, were planned.9 The first in-
terim analysis was planned to take place when 
one third of the total expected events had oc-
curred; the subsequent interim analyses were 
expected to occur yearly after that.
Event-free survival and overall survival were 
estimated by means of the Kaplan–Meier method, 
and 95% confidence intervals of yearly rates were 
estimated by the Rothman method. Hazard ratios 
with adjustment for therapeutic group, histologic 
type, and national group were estimated by the 
Cox model. Subgroup analyses according to three 
baseline characteristics (age, histologic features, 
and therapeutic group) were prespecified.
R esult s
Interim Analyses
The first interim analysis was based on 27 events 
in 310 patients, which corresponded to 37.5% of 
the expected events and a nominal alpha error of 
0.00137. The median follow-up was 11.5 months. 
Event-free survival at 1 year was 94.2% (95% con-
fidence interval [CI], 88.5 to 97.2) in the ritux-
imab–chemotherapy group and 81.5% (95% CI, 
73.0 to 87.8) in the chemotherapy group (hazard 
ratio for event [defined as primary refractory 
disease or first occurrence of progression, re-
lapse after response, death from any cause, or 
second cancer], 0.33; 95% CI, 0.14 to 0.79).10 The 
full results of this interim analysis are presented 
in the Supplementary Appendix.
After the first interim analysis, randomization 
was stopped for efficacy in November 2015 on the 
recommendation of the independent data and 
safety monitoring committee. An additional 120 
patients were subsequently enrolled and treated 
with rituximab and chemotherapy (single-group 
cohort) for prespecified secondary aims; these 
patients are not included in the analyses pre-
sented here. The current analyses are based on 
38 events, corresponding to 52.8% of the expect-
ed events and a nominal alpha error of 0.00562. 
The cumulative alpha error is 0.00699.
Analysis Sets
From December 2011 through November 2015, a 
total of 362 patients were enrolled at 176 cen-
ters. Data from 1 patient were removed owing to 
withdrawal of consent. The 33 patients who 
were still receiving induction or consolidation 
chemotherapy after the closure of randomiza-
tion in November 2015 were recommended to 
receive rituximab and chemotherapy regardless 
of the randomly assigned group. These patients 
were not included in the primary analysis but 
were included in the sensitivity analysis. Thus, 
the main analyses included 328 patients who 
had undergone randomization until August 26, 
2015 (Fig. 1), including 4 patients who were de-
clared to be ineligible: 3 patients after central 
pathological review (1 patient had precursor B-cell 
acute lymphoblastic leukemia and 2 had primary 
mediastinal B-cell lymphoma) and 1 patient who 
had stage III disease and an LDH level that was 
less than two times the upper limit of the nor-
mal range.
Patients and Treatment
The characteristics of the patients at baseline 
were well balanced between the two treatment 
groups (Table 1). A total of 85.7% of the patients 
had Burkitt’s lymphoma. Three patients in the 
chemotherapy group received rituximab (2 owing 
to physicians’ decisions and 1 because of a diag-
nosis of primary mediastinal B-cell lymphoma). 
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All the patients in the rituximab–chemotherapy 
group received rituximab, with 11 patients (7%) 
receiving fewer than six doses (Table S1).
Efficacy
The median follow-up was 39.9 months overall, 
with follow-up of 40.9 months (interquartile 
range, 35.1 to 48.9) in the rituximab–chemo-
therapy group and 39.1 months (interquartile 
range, 34.3 to 49.0) in the chemotherapy group. 
Data regarding the response after the adminis-
tration of the COP regimen and remission at the 
time of assessment are shown in Table S2. In 
the primary analysis, there were 38 events: 10 in 
the rituximab–chemotherapy group and 28 in the 
chemotherapy group (Table 2). Six patients 
Figure 1. Randomization, Treatment, and Follow-up of the Patients.
The 33 patients who were still receiving induction or consolidation chemotherapy after the closure of randomization 
in November 2015 were recommended to receive rituximab and chemotherapy regardless of the randomly assigned 
group; these patients were not included in the main analyses. ALL denotes acute lymphoblastic leukemia, LDH lac-
tate dehydrogenase, PMBL primary mediastinal B-cell lymphoma, and ULN upper limit of the normal range.
362 Patients underwent randomization from
December 2011 through November 2015
181 Were assigned to chemotherapy group
181 Were assigned to rituximab–
chemotherapy group
16 Underwent randomization




(not included in main analyses)
17 Underwent randomization




(not included in main analyses)
165 Were assigned to chemotherapy group
164 Were assigned to rituximab–
chemotherapy group
1 Was excluded owing to
withdrawal of informed consent
164 Were included in chemotherapy group
4 Were ineligible 
1 Had stage III cancer with
LDH <2×ULN
2 Had PMBL
1 Had precursor B-cell ALL
3 Received rituximab
1 Had PMBL
2 Had the assigned regimen changed
 per physician’s decision
11 Received <6 injections of rituximab
156 Were included in follow-up >1 yr
(median follow-up, 39.1 mo)
164 Were included in follow-up >1 yr
(median follow-up, 40.9 mo)
164 Were included in efficacy analysis 164 Were included in efficacy analysis
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Male sex — no. (%) 137 (83.5) 135 (82.3)
Age
Mean — yr 8.6±4.4 9.2±4.0
Range — yr 2–17 2–17
Distribution — no. (%)
<6 yr 56 (34.1) 44 (26.8)
6 to <12 yr 67 (40.9) 73 (44.5)
12 to <15 yr 22 (13.4) 30 (18.3)
≥15 yr 19 (11.6) 17 (10.4)
Pathological diagnosis†
Burkitt’s lymphoma 142 (86.6) 139 (84.8)
Diffuse large B-cell lymphoma 12 (7.3) 19 (11.6)
High-grade B-cell lymphoma, not otherwise 
specified
7 (4.3) 6 (3.7)
Primary mediastinal B-cell lymphoma‡ 2 (1.2) 0
Precursor B-cell acute lymphoblastic leukemia‡ 1 (0.6) 0
Prognosis group
Group B, low risk‡ 1 (0.6) 0
Group B, high risk 82 (50.0) 81 (49.4)
Group C1, without CSF blasts 63 (38.4) 65 (39.6)
Group C3, with CSF blasts 16 (9.8) 18 (11.0)
Primary mediastinal B-cell lymphoma‡ 2 (1.2) 0
Murphy stage
Stage III 73 (44.5) 70 (42.7)
Stage IV 32 (19.5) 32 (19.5)
Leukemic disease, mature B-cell acute leukemia 57 (34.8) 62 (37.8)
Primary mediastinal B-cell lymphoma‡ 2 (1.2) 0
Central nervous system involvement
No 120 (73.2) 119 (72.6)
Yes 44 (26.8) 45 (27.4)
Lactate dehydrogenase
≤2× ULN 18 (11.0) 17 (10.4)
>2× ULN 146 (89.0) 147 (89.6)
Primary site or type
Thorax 6 (3.7) 6 (3.7)
Abdomen or retroperitoneum 95 (57.9) 96 (58.5)
Head and neck, except skin and nodes 9 (5.5) 20 (12.2)
Peripheral lymph node 6 (3.7) 2 (1.2)
Cerebral lymphoma 3 (1.8) 2 (1.2)
Other tumor site 11 (6.7) 8 (4.9)
Clinical presentation of leukemia disease 34 (20.7) 30 (18.3)
*  Percentages may not total 100 because of rounding. CSF denotes cerebrospinal fluid, and ULN upper limit of the nor-
mal range (according to institutional values).
†  These data were obtained from national pathological review in 235 patients (72%) or from local pathological diagnosis.
‡  Patients with these conditions were not eligible for the trial. On central review, these patients were found to be ineli-
gible, but they were included in the intention-to-treat analyses.
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(three in each group) died from toxic events. 
Four patients (two in each group) had primary 
refractory disease. The major between-group dif-
ference in events was observed in relapse or pro-
gression, which occurred in 3 patients in the 
rituximab–chemotherapy group and in 23 in 
the chemotherapy group; all events of relapse or 
progression occurred within 9 months after ran-
domization. A total of 18 of these patients subse-
quently died: all 3 of the patients in the ritux-
imab–chemotherapy group and 15 of the 23 
patients in the chemotherapy group. A second 
cancer developed in 2 patients in the rituximab–
chemotherapy group: 1 patient had melanoma, 
and 1 had fatal histiocytic sarcoma with a t(8;14) 
IGH–MYC anomaly identical to the primary lym-
phoma. In total, 8 patients in the rituximab–
chemotherapy group died (4 deaths were dis-
ease-related, 3 were treatment-related, and 1 was 
from a second cancer), as did 20 in the chemo-
therapy group (17 deaths were disease-related, 
and 3 were treatment-related).
Event-free survival at 3 years was 93.9% (95% 
CI, 89.1 to 96.7) in the rituximab–chemotherapy 
group and 82.3% (95% CI, 75.7 to 87.5) in the 
chemotherapy group (Fig. 2A). In the analysis of 
event-free survival, the hazard ratio for an event 
was 0.32 (95% CI, 0.15 to 0.66; one-sided 
P = 0.00096, which reached the significance level 
required for this second analysis). Overall sur-
vival at 3 years was 95.1% (95% CI, 90.5 to 97.5) 
in the rituximab–chemotherapy group and 87.3% 
(95% CI, 81.2 to 91.6) in the chemotherapy 
group (hazard ratio for death, 0.36; 95% CI, 0.16 
to 0.82) (Fig. 2B).
The sensitivity analysis, which involved 361 
patients (including those in the period between 
August 26, 2015, and November 2015, who were 
recommended to receive rituximab and chemo-
therapy regardless of the randomly assigned 
group), showed similar results. Event-free survival 
at 3 years was 92.8% in the rituximab–chemo-
therapy group and 83.4% in the chemotherapy 
group (hazard ratio for an event, 0.40; 95% CI, 
0.21 to 0.78). Overall survival at 3 years was 
94.3% in the rituximab–chemotherapy group and 
88.5% in the chemotherapy group (hazard ratio 
for death, 0.45; 95% CI, 0.21 to 0.97). The bene-
fit of rituximab was similar across subgroups 
defined according to age, histologic features, 
and therapeutic group (Fig. S2).
Adverse Events
The incidence of rituximab infusion–related reac-
tions was 33.3% during the first infusion (with 
4.3% of the patients having a grade 3 event); the 
incidence decreased to 3.7 to 9.6% during subse-
quent infusions (with 1.0 to 2.1% of the patients 
having a grade 3 event). No immediate infusion-
related grade 4 toxic effect occurred. Treatment-
related toxic effects of grade 4 or higher were 
observed in 35.2% of the patients overall, includ-
ing in 28.9% of the patients after prephase treat-
ment with the COP regimen (Table 3). The most 
frequent adverse events after prephase treatment 
were febrile neutropenia (in 91.7% of the patients), 
infection (in 54.0%), and stomatitis (in 77.5%).
Six patients (1.8% of the patients overall; three 
patients in each group) died from toxic effects. 
Five of the deaths, four of which were from in-
fection, occurred in patients receiving group C 
chemotherapy after the receipt of the first course 
of therapy with cyclophosphamide, vincristine, 
prednisone, doxorubicin, and methotrexate, with 
or without rituximab depending on treatment 
group (in three patients); after the receipt of the 
second course of therapy with cyclophospha-
mide, vincristine, prednisone, doxorubicin, and 
methotrexate, with rituximab (in one patient); or 
after the receipt of a continuous infusion and 
high-dose cytarabine and etoposide, with ritux-
imab (in one patient). One death from toxic 
effects occurred in a patient receiving group B 
chemotherapy who had undergone hemicolecto-
my at diagnosis and died from small-bowel ob-
struction and septic shock after the receipt of 
COPADM2.
The incidence of adverse events of grade 4 or 
higher was 37.7% in the rituximab–chemothera-
py group and 32.7% in the chemotherapy group 
(P = 0.36). In an analysis that was focused on the 
period after the receipt of COP prephase treat-
ment, the incidence of adverse events of grade 4 
or higher was 33.3% in the rituximab–chemo-
therapy group and 24.2% in the chemotherapy 
group (P = 0.07). After prephase treatment, the 
incidence of febrile neutropenia of grade 4 or 
higher was 11.7% in the rituximab–chemother-
apy group and 6.5% in the chemotherapy group 
(P = 0.11), and the incidence of infection of grade 
4 or higher was 18.5% and 11.1%, respectively 
(P = 0.07). No other acute unexpected toxic effects 
were reported in either group. The most frequent 
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Table 2. Number and Type of Events and Number of Deaths.*















All patients 164 164
Death from toxic event 3 3 3 3
Primary refractory disease, 
with viable cells after 
CYVE2 therapy
2 2 2 1
Relapse or progression 23 15 3 3
Second cancer 0 0 2 1
Total no. of events 28 — 10 —
Total no. of deaths — 20 — 8
Group B 84† 81
Death from toxic event 2 2‡ 0 0
Primary refractory disease, 
with viable cells after 
CYVE2 therapy
1 1 1 0
Relapse or progression 11 6 3 3
Second cancer 0 0 1§ 0
Total no. of events 14 — 5 —
Total no. of deaths — 9 — 3
Group C1 64¶ 65
Death from toxic event 1 1 3 3‖
Primary refractory disease, 
with viable cells after 
CYVE2 therapy
1 1 1 1
Relapse or progression 8 5 0 0
Second cancer 0 0 0 0
Total no. of events 10 — 4 —
Total no. of deaths — 7 — 4
Group C3 16 18
Death from toxic event 0 0 0 0
Primary refractory disease, 
with viable cells after 
CYVE2 therapy
0 0 0 0
Relapse or progression 4 4 0 0
Second cancer 0 0 1 1**
Total no. of events 4 — 1 —
Total no. of deaths — 4 — 1
*  CYVE2 denotes the second course of continuous infusion and high-dose cytarabine and etoposide.
†  One patient in the low-risk group B (who did not have an event) was counted in group B.
‡  One patient who was receiving group C1 chemotherapy died after receipt of the first course of therapy with cyclo-
phosphamide, vincristine, prednisone, doxorubicin, and methotrexate.
§  One patient, a 14-year-old girl, received a diagnosis of melanoma that had developed on a congenital skin nevus  
5 months after the diagnosis of Burkitt’s lymphoma.
¶  One patient with primary mediastinal B-cell lymphoma (who did not have an event) was counted in group B, and one 
(who had disease progression) was counted in group C1.
‖  One patient switched to group C3 after receipt of the COP regimen; the death occurred after receipt of the second 
course of group C3 chemotherapy (cyclophosphamide, vincristine, prednisone, doxorubicin, and methotrexate).
**  One patient, a 6-year-old boy, had fatal histiocytic sarcoma with an identical t(8;14) IGH–MYC anomaly, which had 
been diagnosed when he was 16.6 months of age.
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adverse events according to treatment course and 
all adverse events of grade 4 or higher are pre-
sented in Tables S3 and S4, respectively.
Immunoglobulin Status
The percentage of patients with a low IgG level 
(less than the lower limit of the normal range) 
was significantly higher in the rituximab–chemo-
therapy group than in the chemotherapy group 
at the end of therapy (70.3% vs. 46.8%, P = 0.002) 
and at 1 year after inclusion (55.9% vs. 25.4%, 
P<0.001), respectively (Table S5). Approximately 
twice as many patients in the rituximab–chemo-
therapy group as in the chemotherapy group re-
ceived intravenous immune globulin (15.8% vs. 
7.0%). The primary reason for immune globulin 
replacement was a low immunoglobulin level 
without infection (Table S6). At 1 year after en-
rollment, seven patients were still receiving intra-
venous immune globulin in the rituximab–chemo-
therapy group and three in the chemotherapy 
group. Complete and longer follow-up with re-
gard to immune status and late infections have 
not been evaluated.
Discussion
In this randomized, international, phase 3 trial, 
we found that among children and adolescents 
with high-grade, high-risk, mature B-cell lym-
phoma, the addition of six doses of rituximab to 
LMB therapy led to significantly better event-free 
survival outcomes (hazard ratio for an event, 0.32; 
95% CI, 0.15 to 0.66; 3-year event-free survival, 
93.9% in the rituximab–chemotherapy group vs. 
82.3% in the chemotherapy group). The benefit 
was similar across the various therapeutic groups, 
including the group of patients with CNS dis-
ease. Higher 3-year overall survival was also 
observed (95.1% in the rituximab–chemotherapy 
group vs. 87.3% in the chemotherapy group; 
hazard ratio for death, 0.36; 95% CI, 0.16 to 
0.82). Overall, the acute toxic effects that were 
associated with the addition of rituximab main-
ly involved a higher incidence of myelotoxic ef-
fects, but further follow-up is needed to provide 
information on long-term safety because ritux-
imab therapy induced more hypogammaglobu-
linemia than chemotherapy alone.
The benefit of rituximab therapy in this trial 
appeared to be similar to that observed in trials 
involving adult patients. In a randomized French 
trial that compared the addition of four doses of 
rituximab to adult-adapted LMB chemotherapy 
with chemotherapy alone in 257 patients with 
Burkitt’s lymphoma (61% of the patients were 
≥40 years of age), superior 3-year event-free sur-
vival (75% in the rituximab–chemotherapy group 
vs. 62% in the chemotherapy group; hazard ratio 
for event, 0.59; P = 0.02) and overall survival 
(83% vs. 70%; hazard ratio for death, 0.51; 
P = 0.01) were observed.11 A direct comparison of 
Figure 2. Event-free Survival and Overall Survival, According to Treatment 
Group.
Shown are Kaplan–Meier estimates of event-free survival (i.e., freedom 
from primary refractory disease or first occurrence of progression, relapse 
after response, death from any cause, or second cancer) and of overall sur-
vival. Vertical bars represent the Rothman 95% confidence intervals; point 
estimates of 36-month event-free survival and overall survival with 95% 
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(N = 162) P Value
no. of patients (%)
During all therapy
≥1 Adverse event 306 (97.1) 148 (96.7) 158 (97.5)
≥1 Adverse event of grade ≥4 111 (35.2) 50 (32.7) 61 (37.7) 0.36
During COP prephase treatment
≥1 Adverse event 63 (20.0) 31 (20.3) 32 (19.8)
≥1 Adverse event of grade ≥4 27 (8.6) 17 (11.1) 10 (6.2) 0.12
After COP prephase treatment
≥1 Adverse event 303 (96.2) 147 (96.1) 156 (96.3)
≥1 Adverse event of grade ≥4 91 (28.9) 37 (24.2) 54 (33.3) 0.07
Most frequent adverse events after 
COP prephase treatment
Febrile neutropenia 289 (91.7) 139 (90.8) 150 (92.6)
Grade 3 260 (82.5) 129 (84.3) 131 (80.9)
Grade ≥4 29 (9.2) 10 (6.5) 19 (11.7) 0.11
Stomatitis 244 (77.5) 115 (75.2) 129 (79.6)
Grade 3 224 (71.1) 108 (70.6) 116 (71.6)
Grade ≥4 20 (6.3) 7 (4.6) 13 (8.0) 0.21
Enteritis 63 (20.0) 24 (15.7) 39 (24.1)
Grade 3 62 (19.7) 24 (15.7) 38 (23.5)
Grade ≥4 1 (0.3) 0 1 (0.6) 1.00
Infection 170 (54.0) 75 (49.0) 95 (58.6)
Grade 3 123 (39.0) 58 (37.9) 65 (40.1)
Grade ≥4 47 (14.9) 17 (11.1) 30 (18.5) 0.07
Main types of infection
Sepsis 45 (14.3) 17 (11.1) 28 (17.3)
Central venous catheter– 
related infection
38 (12.1) 17 (11.1) 21 (13.0)
Lung infection 32 (10.2) 13 (8.5) 19 (11.7)
Enterocolitis infection 32 (10.2) 18 (11.8) 14 (8.6)
Biologic adverse events
Alanine aminotransferase  
increased
41 (13.0) 18 (11.8) 23 (14.2)
Grade 3 25 (7.9) 12 (7.8) 13 (8.0)
Grade ≥4 16 (5.1) 6 (3.9) 10 (6.2) 0.36
Hypokalemia 36 (11.4) 15 (9.8) 21 (13.0)
Grade 3 28 (8.9) 11 (7.2) 17 (10.5)
Grade ≥4 8 (2.5) 4 (2.6) 4 (2.5) 1.00
*  Shown are the numbers and percentages of patients who had at least one adverse event, those who had at least one 
adverse event of grade 4 or higher, and those who had the most frequent acute adverse events (i.e., events occurring 
in >10% of the patients overall). A total of 13 patients who did not have data on treatment or adverse events or who 
received only prephase treatment (a regimen of cyclophosphamide, vincristine, and prednisone [COP]) were not in-
cluded in this analysis. Only nonhematologic adverse events of grade 3 or higher or cardiac adverse events of grade 2 
or higher were recorded. P values are shown for events of grade 4 or higher.
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outcomes in adults and children is difficult, how-
ever, because the outcomes in children who are 
treated with chemotherapy are superior to those 
in adults, and molecular analyses suggest that 
there is age-related biologic heterogeneity in 
Burkitt’s lymphomagenesis.5,6
The data from this trial suggest that the ad-
dition of rituximab may result in a higher inci-
dence of severe (grade ≥4) acute adverse events 
(primarily febrile neutropenia and infection) af-
ter prephase treatment. Although specific viral 
infections have been reported in approximately 
2% of patients treated with rituximab, we did 
not observe such infections in the rituximab–
chemotherapy group (which included 164 pa-
tients), but longer follow-up is needed.12,13 Two 
patients (1%) in the rituximab–chemotherapy 
group had second cancers: one patient had 
melanoma within a congenital skin nevus, and 
one patient had a clonally related histiocytic 
sarcoma suggesting transdifferentiation of the 
Burkitt’s lymphoma clone. Some reports have 
suggested that among adult patients with lym-
phoma, the introduction of rituximab may in-
crease the risk of a second cancer (especially 
acute myeloid leukemia, thyroid cancer, and 
melanoma),14 but a meta-analysis did not sup-
port this finding.15 Finally, approximately twice 
as many patients in the rituximab–chemotherapy 
group as in the chemotherapy group had a low 
IgG level 1 year after trial inclusion, although 
very few patients received immune globulin re-
placement for infections. An assessment of the 
long-term effects of combining rituximab with 
this chemotherapy regimen in children with non-
Hodgkin’s lymphoma, including data on immune 
status, will be useful.
A previous phase 2 window study involving 
children with newly diagnosed high-grade, ma-
ture B-cell non-Hodgkin’s lymphoma showed 
that 21% of the patients had a complete or par-
tial response during a 5-day window after receiv-
ing a single dose of rituximab16; another study is 
currently comparing one dose of rituximab with 
six doses in children with advanced-stage B-cell 
non-Hodgkin’s lymphoma (ClinicalTrials.gov num-
ber, NCT03206671). With respect to pharmaco-
kinetics, rituximab clearance appears to be relat-
ed to total tumor burden; exposure to rituximab 
decreases as tumor metabolic volume increases. 
Higher rituximab exposure is associated with a 
higher percentage of patients with a response and 
longer progression-free survival among patients 
with diffuse large B-cell lymphoma.17 A small 
cohort study involving children and adolescents 
with high-grade, mature B-cell non-Hodgkin’s 
lymphoma showed some age dependency with 
regard to rituximab pharmacokinetics.18 Thus, 
we are conducting additional pharmacokinetic 
analyses, including examination of the effects of 
age and tumor burden on rituximab disposition.
Although the results of the Inter-B-NHL ritux 
2010 trial showed a benefit with the addition of 
rituximab in the treatment of children with 
high-grade, high-risk, mature B-cell non-Hodg-
kin’s lymphoma, the use of rituximab in chil-
dren with standard-risk B-cell non-Hodgkin’s 
lymphoma (approximately 40% of patients) is 
still questionable, because their survival after 
treatment with chemotherapy alone is very high 
(97 to 98%).19 It is conceivable that the addition 
of rituximab could allow for a reduction of cyto-
toxic chemotherapy; however, given the very poor 
outcome in patients with refractory or relapsed 
disease,20 it would be ethically challenging to 
conduct such a study. Furthermore, although cur-
rent chemotherapy is associated with substantial 
acute toxic effects, deaths from toxic effects are 
rare and the risks of clinically significant long-
term sequelae are relatively modest with the use 
of this chemotherapy backbone.21 To help inform 
such a study, more data are necessary in order to 
evaluate the long-term safety of rituximab ad-
ministered with chemotherapy in children with 
non-Hodgkin’s lymphoma.
This trial showed that the addition of ritux-
imab to chemotherapy was effective therapy in 
children and adolescents with high-risk, high-
grade, mature B-cell non-Hodgkin’s lymphoma 
and resulted in long-term complete remission in 
95% of the patients. In addition, we found an 
effective global framework for academic-based, 
collaborative pediatric groups that leveraged both 
public and private sector support to conduct 
clinical trials involving children with a rare 
cancer.
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